Altmetrics
Downloads
87
Views
31
Comments
0
A peer-reviewed article of this preprint also exists.
This version is not peer-reviewed
Total DLBCL | R-CHOP-like | Salvage therapy | |
n = 246 | n = 194 | n = 52 | |
Age, years | 72.0 (63.0–79.0) | 73.0 (63.0–80.0) | 69.5 (61.5–75.5) |
Sex | |||
Female | 146 (59%) | 109 (56%) | 37 (71%) |
Male | 100 (41%) | 85 (44%) | 15 (29%) |
Comorbidity | |||
Diabetes | 36 (15%) | 32 (16%) | 4 (8%) |
Chronic kidney disease | 14 (6%) | 10 (5%) | 4 (8%) |
Cardiac disease | 38 (15%) | 33 (17%) | 5 (10%) |
Pulmonary disease | 5 (2%) | 4 (2%) | 1 (2%) |
Malignancy | 31 (13%) | 24 (12%) | 7 (13%) |
Ann Arbor stage | |||
I | 39 (16%) | 38 (20%) | 1 (2%) |
II | 55 (22%) | 48 (25%) | 7 (13%) |
III | 44 (18%) | 34 (18%) | 10 (19%) |
IV | 108 (44%) | 74 (38%) | 34 (65%) |
Bone marrow infiltration | |||
Yes | 44 (18%) | 30 (15%) | 14 (27%) |
No | 202 (82%) | 164 (85%) | 38 (73%) |
Extranodal involvement | |||
Yes | 140 (57%) | 102 (53%) | 38 (73%) |
No | 106 (43%) | 92 (47%) | 14 (27%) |
Baseline laboratory data | |||
eGFR < 60 mL/min/1.73 m2 | 61 (25%) | 52 (27%) | 9 (17%) |
T-Bil > 1.0 g/dL | 35 (15%) | 27 (14%) | 8 (16%) |
Albumin < 3.5 g/dL | 87 (36%) | 71 (37%) | 16 (31%) |
LD > 222 IU/L | 147 (60%) | 109 (57%) | 38 (73%) |
CRP > 10 mg/dL | 13 (6%) | 10 (6%) | 3 (6%) |
sIL2R > 2000 U/mL | 97 (40%) | 72 (37%) | 25 (48%) |
WBC < 3.5 × 109 /L | 29 (12%) | 22 (11%) | 7 (13%) |
ANC < 1.5 × 109 /L | 9 (4%) | 8 (4%) | 1 (2%) |
ALC < 0.7 × 109 /L | 54 (22%) | 42 (22%) | 12 (23%) |
Hemoglobin < 12.0 g/dL | 114 (46%) | 92 (47%) | 22 (42%) |
Platelet count < 100 × 109 /L | 32 (13%) | 24 (12%) | 8 (15%) |
Hepatitis viral status | |||
Viral hepatitis | 50 (20%) | 40 (21%) | 10 (19%) |
HCV | 15 (6%) | 13 (7%) | 2 (4%) |
HBV | 43 (17%) | 33 (17%) | 10 (19%) |
HBsAg + | 5 (2%) | 3 (2%) | 2 (4%) |
anti-HBs + | 27 (11%) | 21 (11%) | 6 (12%) |
anti-HBc + | 34 (14%) | 28 (14%) | 6 (12%) |
Developed FN during the first therapy cycle |
Did not develop FN during the first therapy cycle |
p-value | |
n = 37 | n = 157 | ||
Age ≥ 65 years | 26 (70%) | 112 (71%) | 0.90 |
Sex: male | 21 (57%) | 88 (56%) | 0.94 |
Comorbidity | |||
Diabetes | 4 (11%) | 28 (18%) | 0.30 |
Chronic kidney disease | 2 (5%) | 8 (5%) | 0.94 |
Cardiac disease | 7 (19%) | 26 (17%) | 0.73 |
Pulmonary disease | 2 (5%) | 2 (1%) | 0.11 |
Malignancy | 6 (16%) | 18 (11%) | 0.43 |
Baseline laboratory data | |||
WBC < 3.5 × 109 /L | 5 (14%) | 17 (11%) | 0.64 |
Hemoglobin < 12.0 g/dL | 20 (54%) | 72 (46%) | 0.37 |
Platelet < 100 × 109 /L | 11 (30%) | 13 (8%) | < 0.001 |
ANC < 1.5 × 109 /L | 2 (5%) | 6 (4%) | 0.67 |
ALC < 0.7 × 109 /L | 20 (54%) | 22 (14%) | < 0.001 |
T-Bil > 1.0 g/dL | 6 (16%) | 21 (14%) | 0.73 |
Albumin < 3.5 g/dL | 22 (63%) | 49 (31%) | < 0.001 |
LD > 222 IU/L | 27 (75%) | 82 (53%) | 0.014 |
CRP > 10 mg/dL | 5 (14%) | 5 (4%) | 0.02 |
eGFR < 60 mL/min/1.73 m2 |
13 (35%) | 39 (25%) | 0.2 |
sIL2R > 2000 U/mL | 26 (70%) | 46 (29%) | < 0.001 |
Ann Arbor stage: Advanced (III–IV) |
30 (83%) | 78 (50%) | < 0.001 |
Extranodal involvement | 27 (73%) | 75 (48%) | 0.006 |
Bone marrow infiltration | 12 (32%) | 18 (11%) | 0.002 |
Hepatitis viral status | |||
Viral hepatitis | 16 (43%) | 24 (15%) | < 0.001 |
HCV | 8 (22%) | 5 (3%) | < 0.001 |
HBV | 11 (30%) | 22 (14%) | 0.022 |
HBsAg + | 1 (3%) | 2 (1%) | 0.53 |
anti-HBs + | 6 (16%) | 15 (10%) | 0.24 |
anti-HBc + | 11 (30%) | 17 (11%) | 0.003 |
n = 191 | ||||
Odds ratio [95% CI] | β coefficient [95% CI] | Score | p-value | |
ALC < 0.7 × 109 /L | 6.32 [2.51–15.92] | 1.84 [0.92–2.77] | 2 | < 0.001 |
sIL2R > 2000 U/mL | 3.05 [1.21–7.67] | 1.12 [0.19–2.04] | 1 | 0.018 |
Extranodal involvement | 2.94 [1.08–7.99] | 1.08 [0.08–2.08] | 1 | 0.034 |
Viral hepatitis | 4.85 [1.85–12.74] | 1.58 [0.61–2.54] | 1 | 0.001 |
n = 191 | |||
Logistic regression β coefficient [95% CI] |
Bootstrapped β coefficient [95% CI] |
Score | |
ALC < 0.7 × 109 /L | 1.84 [0.92–2.77] | 1.97 [0.81–2.88] | 2 |
sIL2R > 2000 U/mL | 1.12 [0.19–2.04] | 1.17 [0.09–2.14] | 1 |
Extranodal involvement | 1.08 [0.08–2.08] | 1.18 [0.02–2.14] | 1 |
Viral hepatitis | 1.58 [0.61–2.54] | 1.68 [0.55–2.61] | 1 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
supplementary.docx (5.63MB )
Submitted:
01 November 2023
Posted:
02 November 2023
You are already at the latest version
A peer-reviewed article of this preprint also exists.
supplementary.docx (5.63MB )
This version is not peer-reviewed
Submitted:
01 November 2023
Posted:
02 November 2023
You are already at the latest version
Total DLBCL | R-CHOP-like | Salvage therapy | |
n = 246 | n = 194 | n = 52 | |
Age, years | 72.0 (63.0–79.0) | 73.0 (63.0–80.0) | 69.5 (61.5–75.5) |
Sex | |||
Female | 146 (59%) | 109 (56%) | 37 (71%) |
Male | 100 (41%) | 85 (44%) | 15 (29%) |
Comorbidity | |||
Diabetes | 36 (15%) | 32 (16%) | 4 (8%) |
Chronic kidney disease | 14 (6%) | 10 (5%) | 4 (8%) |
Cardiac disease | 38 (15%) | 33 (17%) | 5 (10%) |
Pulmonary disease | 5 (2%) | 4 (2%) | 1 (2%) |
Malignancy | 31 (13%) | 24 (12%) | 7 (13%) |
Ann Arbor stage | |||
I | 39 (16%) | 38 (20%) | 1 (2%) |
II | 55 (22%) | 48 (25%) | 7 (13%) |
III | 44 (18%) | 34 (18%) | 10 (19%) |
IV | 108 (44%) | 74 (38%) | 34 (65%) |
Bone marrow infiltration | |||
Yes | 44 (18%) | 30 (15%) | 14 (27%) |
No | 202 (82%) | 164 (85%) | 38 (73%) |
Extranodal involvement | |||
Yes | 140 (57%) | 102 (53%) | 38 (73%) |
No | 106 (43%) | 92 (47%) | 14 (27%) |
Baseline laboratory data | |||
eGFR < 60 mL/min/1.73 m2 | 61 (25%) | 52 (27%) | 9 (17%) |
T-Bil > 1.0 g/dL | 35 (15%) | 27 (14%) | 8 (16%) |
Albumin < 3.5 g/dL | 87 (36%) | 71 (37%) | 16 (31%) |
LD > 222 IU/L | 147 (60%) | 109 (57%) | 38 (73%) |
CRP > 10 mg/dL | 13 (6%) | 10 (6%) | 3 (6%) |
sIL2R > 2000 U/mL | 97 (40%) | 72 (37%) | 25 (48%) |
WBC < 3.5 × 109 /L | 29 (12%) | 22 (11%) | 7 (13%) |
ANC < 1.5 × 109 /L | 9 (4%) | 8 (4%) | 1 (2%) |
ALC < 0.7 × 109 /L | 54 (22%) | 42 (22%) | 12 (23%) |
Hemoglobin < 12.0 g/dL | 114 (46%) | 92 (47%) | 22 (42%) |
Platelet count < 100 × 109 /L | 32 (13%) | 24 (12%) | 8 (15%) |
Hepatitis viral status | |||
Viral hepatitis | 50 (20%) | 40 (21%) | 10 (19%) |
HCV | 15 (6%) | 13 (7%) | 2 (4%) |
HBV | 43 (17%) | 33 (17%) | 10 (19%) |
HBsAg + | 5 (2%) | 3 (2%) | 2 (4%) |
anti-HBs + | 27 (11%) | 21 (11%) | 6 (12%) |
anti-HBc + | 34 (14%) | 28 (14%) | 6 (12%) |
Developed FN during the first therapy cycle |
Did not develop FN during the first therapy cycle |
p-value | |
n = 37 | n = 157 | ||
Age ≥ 65 years | 26 (70%) | 112 (71%) | 0.90 |
Sex: male | 21 (57%) | 88 (56%) | 0.94 |
Comorbidity | |||
Diabetes | 4 (11%) | 28 (18%) | 0.30 |
Chronic kidney disease | 2 (5%) | 8 (5%) | 0.94 |
Cardiac disease | 7 (19%) | 26 (17%) | 0.73 |
Pulmonary disease | 2 (5%) | 2 (1%) | 0.11 |
Malignancy | 6 (16%) | 18 (11%) | 0.43 |
Baseline laboratory data | |||
WBC < 3.5 × 109 /L | 5 (14%) | 17 (11%) | 0.64 |
Hemoglobin < 12.0 g/dL | 20 (54%) | 72 (46%) | 0.37 |
Platelet < 100 × 109 /L | 11 (30%) | 13 (8%) | < 0.001 |
ANC < 1.5 × 109 /L | 2 (5%) | 6 (4%) | 0.67 |
ALC < 0.7 × 109 /L | 20 (54%) | 22 (14%) | < 0.001 |
T-Bil > 1.0 g/dL | 6 (16%) | 21 (14%) | 0.73 |
Albumin < 3.5 g/dL | 22 (63%) | 49 (31%) | < 0.001 |
LD > 222 IU/L | 27 (75%) | 82 (53%) | 0.014 |
CRP > 10 mg/dL | 5 (14%) | 5 (4%) | 0.02 |
eGFR < 60 mL/min/1.73 m2 |
13 (35%) | 39 (25%) | 0.2 |
sIL2R > 2000 U/mL | 26 (70%) | 46 (29%) | < 0.001 |
Ann Arbor stage: Advanced (III–IV) |
30 (83%) | 78 (50%) | < 0.001 |
Extranodal involvement | 27 (73%) | 75 (48%) | 0.006 |
Bone marrow infiltration | 12 (32%) | 18 (11%) | 0.002 |
Hepatitis viral status | |||
Viral hepatitis | 16 (43%) | 24 (15%) | < 0.001 |
HCV | 8 (22%) | 5 (3%) | < 0.001 |
HBV | 11 (30%) | 22 (14%) | 0.022 |
HBsAg + | 1 (3%) | 2 (1%) | 0.53 |
anti-HBs + | 6 (16%) | 15 (10%) | 0.24 |
anti-HBc + | 11 (30%) | 17 (11%) | 0.003 |
n = 191 | ||||
Odds ratio [95% CI] | β coefficient [95% CI] | Score | p-value | |
ALC < 0.7 × 109 /L | 6.32 [2.51–15.92] | 1.84 [0.92–2.77] | 2 | < 0.001 |
sIL2R > 2000 U/mL | 3.05 [1.21–7.67] | 1.12 [0.19–2.04] | 1 | 0.018 |
Extranodal involvement | 2.94 [1.08–7.99] | 1.08 [0.08–2.08] | 1 | 0.034 |
Viral hepatitis | 4.85 [1.85–12.74] | 1.58 [0.61–2.54] | 1 | 0.001 |
n = 191 | |||
Logistic regression β coefficient [95% CI] |
Bootstrapped β coefficient [95% CI] |
Score | |
ALC < 0.7 × 109 /L | 1.84 [0.92–2.77] | 1.97 [0.81–2.88] | 2 |
sIL2R > 2000 U/mL | 1.12 [0.19–2.04] | 1.17 [0.09–2.14] | 1 |
Extranodal involvement | 1.08 [0.08–2.08] | 1.18 [0.02–2.14] | 1 |
Viral hepatitis | 1.58 [0.61–2.54] | 1.68 [0.55–2.61] | 1 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
Masaya Morimoto
et al.
,
2023
Mark Kristjanson
et al.
,
2023
© 2024 MDPI (Basel, Switzerland) unless otherwise stated